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Abstract: Purpose The objective of this study was to evaluate and compare the clinical performance of
samfilcon A, a unique, polyvinylpyrrolidone (PVP)-containing, silicone hydrogel contact lens with that of
the balafilcon A silicone hydrogel contact lens when worn on a 7-day extended wear basis. Subjects and
Methods A total of 669 subjects completed this 12-month, controlled, parallel group, masked, randomized
study; of these, 340 wore samfilcon A lenses and 329 balafilcon A lenses. Subjects wore their respective
assigned lenses bilaterally on a 7-day extended wear basis. On the seventh night of each wearing week,
lenses were removed, cleaned, and disinfected using Biotrue multi-purpose solution (MPS), then re-
inserted the following morning. Lenses were replaced with new lenses monthly. At each follow-up visit,
investigators completed a slit lamp evaluation, and subjects rated lenses based upon a predefined set of
performance criteria. Results The samfilcon A lens performed comparably to the balafilcon A lens in terms
of most graded and ungraded slit lamp findings, differing significantly only for corneal staining Grade
2 or greater, which favored samfilcon A, and anterior segment abnormalities, which favored balafilcon
A. Subjects rated both lenses highly when queried about various lens-wearing characteristics. When
comparing the number of subjects with findings on either eye on at least one follow-up visit, the two
lenses were comparable in many aspects but favored samfilcon A with respect to cleanliness upon removal,
overall comfort, comfort at end of day, dryness, vision, vision in low light, vision at end of day, and overall
impression (all p < 0.05). Conclusion While subjects rated both highly, samfilcon A lenses worn for 7-day
extended wear and replaced on a monthly basis performed comparably to or better than balafilcon A
lenses when worn for the same 7-day wear time and replacement cycle.
DOI: https://doi.org/10.2147/OPTH.S268286






The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Reindel, William; Mosehauer, Gary; Rah, Marjorie; Proskin, Howard; Steffen, Robert (2020). Clinical




O R I G I N A L  R E S E A R C H
Clinical Performance of Samfilcon A, a Unique 
Silicone Hydrogel Lens, on a 7-Day Extended 
Wear Basis





Howard Proskin 2 
Robert Steffen1
1Vision Care, Bausch & Lomb 
Incorporated, Rochester, NY, USA; 
2Howard M. Proskin & Associates, 
Rochester, NY, USA 
Purpose: The objective of this study was to evaluate and compare the clinical performance 
of samfilcon A, a unique, polyvinylpyrrolidone (PVP)-containing, silicone hydrogel contact 
lens with that of the balafilcon A silicone hydrogel contact lens when worn on a 7-day 
extended wear basis.
Subjects and Methods: A total of 669 subjects completed this 12-month, controlled, 
parallel group, masked, randomized study; of these, 340 wore samfilcon A lenses and 329 
balafilcon A lenses. Subjects wore their respective assigned lenses bilaterally on a 7-day 
extended wear basis. On the seventh night of each wearing week, lenses were removed, 
cleaned, and disinfected using Biotrue multi-purpose solution (MPS), then re-inserted the 
following morning. Lenses were replaced with new lenses monthly. At each follow-up visit, 
investigators completed a slit lamp evaluation, and subjects rated lenses based upon 
a predefined set of performance criteria.
Results: The samfilcon A lens performed comparably to the balafilcon A lens in terms of most 
graded and ungraded slit lamp findings, differing significantly only for corneal staining Grade 2 
or greater, which favored samfilcon A, and anterior segment abnormalities, which favored 
balafilcon A. Subjects rated both lenses highly when queried about various lens-wearing 
characteristics. When comparing the number of subjects with findings on either eye on at least 
one follow-up visit, the two lenses were comparable in many aspects but favored samfilcon 
A with respect to cleanliness upon removal, overall comfort, comfort at end of day, dryness, 
vision, vision in low light, vision at end of day, and overall impression (all p < 0.05).
Conclusion: While subjects rated both highly, samfilcon A lenses worn for 7-day extended 
wear and replaced on a monthly basis performed comparably to or better than balafilcon 
A lenses when worn for the same 7-day wear time and replacement cycle.
Keywords: PVP, contact lens, extended wear
Introduction
Today’s contact lens wearers have more lens options from which to choose than 
ever.1 Daily-disposable lenses are designed to be worn for a single day, then 
disposed of upon removal, while planned-replacement lenses are designed to be 
worn daily and cleaned and disinfected nightly, then disposed of after a maximum 
number of wearing days. Extended-wear lenses are designed to be worn for up to 
a maximum number of days between cleaning and disinfection, and disposed of 
after a maximum number of wearing days.
Four leading, currently marketed soft lenses are indicated for daily wear or 
extended wear for up to 7 days between removals for cleaning and disinfection or 
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disposal as recommended by the eye care practitioner, 
these being senofilcon A (Acuvue Oasys, Johnson & 
Johnson Vision Care, Jacksonville, FL),2 samfilcon 
A (Bausch + Lomb ULTRA, Bausch & Lomb 
Incorporated, Rochester, NY),3 comfilcon A (Biofinity, 
CooperVision, Pleasanton, CA),4 and lotrafilcon B (Air 
Optix Aqua, Alcon, Ft. Worth, TX).5 Two currently mar-
keted lenses are approved for daily wear or extended wear 
up to 30 days between removals, these being balafilcon 
A (PureVision, Bausch & Lomb Incorporated)6 and lotra-
filcon A (Air Optix Night and Day, Alcon).7 Both 30-day 
extended wear lenses were initially approved for daily 
wear or weekly extended wear but achieved monthly 
extended wear indications after the appropriate clinical 
trials.
Modern contact lens material development is complex 
as lens materials must withstand a range of user conditions 
influenced by environmental factors (eg, low relative 
humidity),8,9 demanding visual tasks (eg, increased atten-
tion to digital devices),10,11 digital screen viewing that 
affects both blink dynamics and tear film 
characteristics,11–13 individual characteristics (eg, tear 
film anomalies),14 and lens care factors (eg, rub/rinse 
manipulation).15 Advancements in contact lens materials 
and design can help sustain comfort and vision across 
recommended replacement cycles. Manufacturers often 
include wetting agents in lens formulations to promote 
water retention, most notably phosphorylcholine (PC)16 
and polyvinylpyrrolidone (PVP).17 Such agents are 
desirable as contact lens components due to their water- 
attracting properties. Samfilcon A, a unique, 
PVP-containing, silicone hydrogel lens,3 was designed to 
retain moisture and maintain a persistent, smooth tear film 
surface.18 Synthesis of the samfilcon A lens polymer was 
described in detail previously.19 Briefly, samfilcon A is 
a silicone hydrogel fabricated from a proprietary siloxane 
macromer and NVP monomer. The lens material was 
designed to polymerize in two kinetic phases, with the 
rapid formation of a silicone network, followed by the 
later formation of a PVP internal wetting agent. The mate-
rial and process are designed to deliver a smooth, durable 
surface for spreading the tear film, reducing friction, and 
providing precision optics. Maintaining the key perfor-
mance characteristics throughout the recommended repla-
cement cycle plays an important role in wearer 
satisfaction.
The samfilcon A lens performs well clinically when 
worn on a daily wear basis with monthly lens replacement. 
In one study, 341 patients rated samfilcon A better than 
their respective habitual lenses in terms of comfort, vision, 
and on-eye lens characteristics after a 2-week period of 
daily wear.20 In the same study, 226 digital device users (3 
hours or more daily use) that wore their respective habitual 
lenses at least 12 hours daily and self-reported dryness 
and/or blurry/fluctuating vision with contact lens wear, 
similarly rated samfilcon A lenses superior to their habi-
tual lenses in terms of comfort, dryness, redness, vision, 
and on-eye lens characteristics after a 2-week period of 
daily wear.21 In a different study, high samfilcon A lens 
ratings persisted across the manufacturer-recommended 
monthly replacement schedule, as well as over 3 months 
of daily wear, with lenses cleaned and disinfected nightly 
and replaced monthly.22 As FDA only recently approved 
samfilcon A lenses for 7-day extended wear in the United 
States (US),23 it is of interest to know how these lenses 
perform when worn on an extended-wear basis relative to 
control lenses. Therefore, the objective of the present 
study was to evaluate the clinical performance of samfil-
con A as a 7-day extended wear lens with monthly repla-
cement, and compare to balafilcon A,24 an approved 
30-day extended wear lens, worn in this study on the 
same basis as samfilcon A.
Materials and Methods
Subjects and Lenses
The Quorum Institutional Review Board approved the 
study protocol prior to subject recruitment, and the trial 
was conducted in accordance with the Declaration of 
Helsinki. A total of 36 investigators across 36 investiga-
tive sites in the US participated in this 12-month rando-
mized, parallel, investigator-masked study. All potential 
study subjects provided informed consent prior to the 
determination of eligibility. Eligible subjects were myo-
pic, adapted planned-replacement, soft contact lens wear-
ers aged 18 to 40 on the date of informed consent. All 
subjects required lens correction from −0.50 diopters (D) 
to −6.00 D in each eye and were correctable through 
spherocylindrical refraction to 32 letters (0.3 logMAR 
visual acuity) or better (distance, high contrast) in each 
eye, had clear central corneas, and were free of any ante-
rior segment disorders, any graded corneal infiltrate, and 
any other graded slit lamp finding of Grade 2 or greater at 
screening.
At the baseline screening visit, eligible subjects were 
randomized to receive either samfilcon A (test) or 
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                                                
Clinical Ophthalmology 2020:14 3458

























































































Powered by TCPDF (www.tcpdf.org)
balafilcon A contact lenses (control) and were dispensed 
their respective assigned lenses. Subjects wore lenses 
bilaterally on a 7-day/6-night extended wear basis with 
monthly replacement. On the seventh night of each 
week, lenses were removed, cleaned, and disinfected 
using Biotrue multi-purpose solution (MPS) (Bausch & 
Lomb Incorporated)25 according to the manufacturer’s 
instructions per the product package insert, then re- 
inserted the following morning.
Subjects returned to the clinic for assessment 1 day, 1 
week, 1 month, 3 months, 6 months, 9 months, and 12 
months after the initial screening/dispensing visit. In addi-
tion, subjects returned to the clinic for unscheduled visits 
whenever they experienced problems with their lenses. 
Lenses were provided at the Screening/Dispensing, 
3-Month, 6-Month, and 9-Month Follow-Up Visits to 
maintain a monthly replacement schedule.
Qualitative and Quantitative Assessment
At each scheduled and unscheduled follow-up visit, 
investigators completed a slit lamp evaluation and 
examined subjects for indications of adverse events 
(AEs). Slit lamp signs of epithelial edema, epithelial 
microcysts, limbal injection, bulbar injection, corneal 
infiltrates, corneal neovascularization, upper lid tarsal 
conjunctival abnormalities, and corneal staining were 
graded using an ordinal, text-based scale from which 
numeric grades in integer steps were assigned, 0 (no 
finding), 1 (trace), 2 (mild), 3 (moderate) and 4 (severe). 
Fluorescein staining grades were computed as the max-
imum grade taken within each of five different corneal 
locations (central, inferior, nasal, superior, and tem-
poral). Other ungraded slit lamp findings, including 
new corneal scars, corneal striae, conjunctivitis, external 
adnexa abnormalities, and other anterior segment 
abnormalities, were marked as either present or absent 
for each eye.
Subjects rated lenses based upon comfort, vision, low- 
light vision, and cleanliness using a 0 to 100 scale, with 0 
denoting the least favorable and 100 denoting the most 
favorable rating. For context, descriptors were added to the 
rating scale for each category. As an example, the “overall 
comfort” category designated 100 as “excellent; cannot be 
felt,” 80 as “very comfortable; just felt occasionally,” 60 as 
“comfortable; noticeable but not irritating,” 40 as “uncom-
fortable; irritating or annoying,” 20 as “very uncomforta-
ble; very irritating or annoying,” and 0 as “painful; 
difficult to wear lenses.”
Statistical Analysis
The two primary objectives of the statistical analyses were 
1. to provide a high-level, descriptive overview of the data, 
and 2. to provide an overview comparison between the 
treatment groups with respect to the occurrence of unto-
ward events (as defined below) observed during each sub-
ject’s follow-up visits, including unscheduled visits. The 
manner by which these were addressed is described below. 
A significance level of α = 0.05 was utilized for all 
reported statistical tests of hypotheses.
Graded Slit Lamp Findings
To provide a descriptive overview of the graded slit lamp 
findings, the distribution of scores for each graded slit 
lamp parameter tallied all individual eye-wise scores 
(both OD and OS) for every subject at every follow-up 
assessment. No statistical analysis was performed as these 
data do not represent independent sampling units. To 
investigate untoward events for each graded slit lamp 
parameter, each subject was categorized according to 
whether or not a finding of grade 2 or higher was recorded 
on either eye (OD or OS) at any follow-up visit. The 
number and proportion of subjects for whom such findings 
were observed was tabulated, and the proportions were 
compared between lens groups using Fisher’s exact test.
Ungraded Slit Lamp Findings
For all ungraded slit lamp parameters, the comparison of 
untoward events also serves as a useful overview. Each 
subject was categorized according to whether or not 
a positive finding was recorded on either eye (OD or 
OS) at any follow-up visit. The number and proportion 
of subjects for whom such findings were observed were 
tabulated, and the proportions were compared between 
lens groups using Fisher’s exact test.
Symptoms/Complaints Scores
For each symptom/complaint, the descriptive overview 
was based upon the overall mean score for each subject, 
which was determined as follows: (1) the average score 
across OD and OS was calculated for each visit; (2) the 
mean of these per-visit averages was then calculated 
across all follow-up visits at which the subject presented 
data for the symptom. A summary of the subject-wise 
overall mean scores was tabulated. No statistical analysis 
was performed as these data do not represent independent 
sampling units.
To investigate untoward events, each subject was cate-
gorized according to whether or not an unfavorable finding 
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(score <50) was recorded on either eye (OD or OS) at any 
follow-up visit. The number and proportion of subjects for 
whom such unfavorable findings were observed was tabu-
lated, and the proportions were compared between lens 
groups using Fisher’s exact test.
Results
Subject Demographics
Demographics of dispensed subjects are shown in Table 1. 
The samfilcon A and balafilcon A subgroups did not differ 
with respect to age, gender, or race (all p ≥ 0.05).
All 816 enrolled subjects (406 and 410 randomized to 
samfilcon A and balafilcon A, respectively) were given 
a baseline examination. One eligible subject randomized to 
samfilcon A was not dispensed lenses, and ten subjects (two 
randomized to samfilcon A and eight to balafilcon A) were 
ultimately determined ineligible to complete the study and 
disenrolled (Figure 1). As such, statistical comparisons were 
made using data from a nominal population of 403 and 402 
subjects, randomized to samfilcon A and balafilcon A, respec-
tively, including all scheduled visits, as well as 267 unsched-
uled visits (142 for the samfilcon A group, and 125 for the 
balafilcon A group). The actual number of observations for 
each group was up to 3 less than the nominal number for some 
measured parameters due to missing data from the investiga-
tors and was used in all hypothesis testing calculations.
Of 805 subjects who were dispensed lenses, 669 
(83.1%) completed the study. Of those that did not complete 
the study, only 11 eyes (0.01%) were discontinued due to an 
AE (all non-serious), while 58 were lost to follow-up and 80 
voluntarily discontinued the study. When an AE occurred in 
one eye only, the subject and his/her contralateral eye was 
also discontinued from the study.
The distribution of graded slit lamp findings is summar-
ized in Table 2. Follow-up scores obtained on both right and 
left eyes of all subjects for each finding, lens group, and lens 
grade are reported. Noteworthy is how few occurrences of 
greater than Grade 2 slit lamp findings were observed, with 
only four Grade 4 findings (one corneal infiltrate and three 
upper lid tarsal conjunctival abnormalities), and few Grade 3 
findings (18 upper lid tarsal conjunctival abnormalities, 14 
Table 1 Demographics of Eligible Dispensed Subjects






Mean ± SD 29.8 ± 6.2 29.2 ± 6.1 0.17#
Gender: n (%)
Female 263 (65.3) 265 (65.9) 0.84§
Male 140 (34.7) 137 (34.1)
Race: n (%)
White 326 (80.9) 328 (81.6) 0.63§
Black/African American 33 (8.2) 30 (7.5)
Asian 15 (3.7) 19 (4.7)
Other 25 (6.2) 18 (4.5)
Refused to Answer 4 (1.0) 7 (1.7)
Notes: §Between-group p-value comparing category proportions based on chi- 
squared test. The test for race excluded subjects that refused to answer. #Between- 
group p-value comparing mean scores based on two-sample t-test.
Figure 1 Subject enrollment flow chart.
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limbal injection, 14 bulbar injection, 5 corneal infiltrates, 
and 9 corneal staining).
The number of subjects with Grade 2 or greater finding 
on either eye on at least one follow-up visit appears in 
Table 3 for both lenses. The two lenses were comparable 
in all graded conditions except for corneal staining, which 
favored samfilcon A (p < 0.05).
The number of subjects with ungraded slit lamp findings 
present on either eye on at least one follow-up visit appears in 
Table 4 for both lenses. The two lenses were comparable in 
most aspects but favored balafilcon A (p < 0.05) with respect 
to other anterior segment abnormalities, the majority of 
which for both groups were inconsequential conjunctival 
findings such as nevi, pinguecula, pterygium, etc.
Lens Performance
Subjects rated symptoms/complaints at each visit (rating 
scale 0 to 100, with 100 being the most favorable score). 
A descriptive summary of the subject-wise overall mean 
scores for all symptom/complaint parameters over all fol-
low-up visits is shown in Table 5. However, both lenses 
scored highly, with most mean scores exceeding 90, and 
all mean scores exceeding 80.
The number of subjects with unfavorable finding on either eye 
on at least one follow-up visit appears in Table 6 for both lenses. 
The two lenses were comparable in many aspects but favored 
samfilcon A with respect to cleanliness upon removal, overall 
comfort, comfort at end of day, dryness, vision, vision in low 
light, vision at end of day, and overall impression (all p < 0.05).
Table 2 Graded Slit Lamp Findings Over All Follow-Up Visits
Finding Lens Group Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Number of Eyes (% of Eyes)
Epithelial Edema Samfilcon A 5470 (99.5) 19 (0.35) 6 (0.11) 0 (0) 0 (0)
Balafilcon A 5358 (99.4) 28 (0.52) 5 (0.09) 0 (0) 0 (0)
Epithelial Microcysts Samfilcon A 5481 (99.8) 14 (0.25) 0 (0) 0 (0) 0 (0)
Balafilcon A 5371 (99.6) 19 (0.35) 1 (0.02) 0 (0) 0 (0)
Limbal Injection Samfilcon A 5154 (93.8) 314 (5.7) 20 (0.36) 7 (0.13) 0 (0)
Balafilcon A 5027 (93.3) 345 (6.4) 12 (0.22) 7 (0.13) 0 (0)
Bulbar Injection Samfilcon A 5019 (91.3) 434 (7.9) 34 (0.62) 8 (0.15) 0 (0)
Balafilcon A 4922 (91.3) 437 (8.1) 26 (0.48) 6 (0.11) 0 (0)
Corneal Infiltrates Samfilcon A 5459 (99.3) 19 (0.35) 13 (0.24) 3 (0.05) 1 (0.02)
Balafilcon A 5378 (99.8) 7 (0.13) 4 (0.07) 2 (0.04) 0 (0)
Corneal Neovascularization Samfilcon A 5349 (97.3) 146 (2.7) 0 (0) 0 (0) 0 (0)
Balafilcon A 5229 (97.0) 162 (3.0) 0 (0) 0 (0) 0 (0)
Upper Lid Tarsal Conjunctival Abnormalities Samfilcon A 4197 (76.4) 1204 (21.9) 80 (1.46) 12 (0.22) 2 (0.04)
Balafilcon A 3945 (73.2) 1336 (24.8) 103 (1.91) 6 (0.11) 1 (0.02)
Corneal Staining Samfilcon A 3781 (79.9) 918 (19.4) 30 (0.63) 6 (0.13) 0 (0)
Balafilcon A 3523 (76.0) 1021 (22.0) 89 (1.92) 3 (0.06) 0 (0)
Note: Distribution is based on all individual follow-up eye visits (including both OD and OS) for all subjects.
Table 3 Subject-Wise Slit Lamp Findings Grade 2 or Greater 
Over All Follow-Up Visits
Finding Number (Percent) of 
Subjects with Grade 2 or 
Greater Finding on Either 





A (n = 402)
Balafilcon 
A (n = 400)
Epithelial Edema 4 (1.0) 4 (1.0) > 0.99
Epithelial Microcysts 0 (0) 1 (0.3) 0.50
Limbal Injection 21 (5.2) 14 (3.5) 0.30
Bulbar Injection 33 (8.2) 23 (5.8) 0.21
Corneal Infiltrates 12 (3.0) 4 (1.0) 0.07
Corneal Neovascularization 0 (0) 0 (0) NA
Upper Lid Tarsal 
Conjunctival Abnormalities
27 (6.7) 39 (9.8) 0.12
Corneal Staining# 27 (6.7) 46 (11.6) 0.02*
Notes: †Between-treatment p-value comparing proportions based on Fisher’s 
exact test. #n = 401 for samfilcon A and 397 for balafilcon A for this parameter 
only. *Difference deemed significant at p < 0.05. 
Abbreviation: NA, not applicable.
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Discussion
The objective of this study was to compare the respective 
performances of samfilcon A and balafilcon A contact 
lenses when worn for 7-days/6 nights of extended wear 
and replaced on a monthly basis.
Slit lamp findings Grade 2 or greater were comparable 
for both lens types for all measured conditions except for 
corneal staining, which favored samfilcon A (p < 0.05; 
Table 3). Ungraded slit lamp findings were comparable for 
both lens types except for other anterior segment abnorm-
alities, which favored balafilcon A (p < 0.05; Table 4).
Subjects rated both lenses highly with respect to vision 
and comfort (Table 5). The two lenses were comparable in 
most aspects but favored samfilcon A with respect to lens 
cleanliness upon removal, overall comfort, comfort at end 
of day, vision, vision in low light, vision at end of day, 
dryness, and overall impression (all p < 0.05; Table 6).
Balafilcon A lenses have been worn successfully on an 
extended wear basis for nearly two decades. Numerous 
clinical studies support the safety and effectiveness of 
the lens. Balafilcon A lenses worn in the same eye over 
4 months on a 7-day extended wear basis and replaced 
weekly induced significantly less bulbar and limbal injec-
tion and corneal vascularization in 18 subjects than did 
Table 4 Subject-Wise Ungraded Slit Lamp Findings Over All 
Follow-Up Visits
Finding Number (Percent) of 
Subjects with Finding on 




A (n = 402)
Balafilcon 
A (n = 400)
New Corneal Scars 8 (2.0) 2 (0.5) 0.11
Corneal Striae 2 (0.5) 0 (0) 0.50
Conjunctivitis 18 (4.5) 18 (4.5) > 0.99
External Adnexa 
Abnormalities




59 (15) 38 (9.5) 0.03*
Notes: †Between-treatment p-value comparing proportions based on Fisher’s 
exact test. *Difference deemed significant at p < 0.05.
Table 5 Symptom/Complaint Scores Over All Follow-Up Visits 
(Dispensed Eyes)
Symptom/Complaint Mean Score ± Sdev
n Samfilcon A n Balafilcon A
Burning/Stinging Upon 
Insertion
400 95.8 ± 7.3 398 93.9 ± 10.0
Ease of Handling/Insertion 400 95.9 ± 7.7 398 94.7 ± 8.4
Vision Upon Insertion 400 96.3 ± 6.0 398 94.5 ± 8.7
Comfort Upon Insertion 400 95.2 ± 7.1 398 92.2 ± 10.3
Ease of Handling/Removal 400 96.1 ± 6.7 399 94.9 ± 8.1
Lens Cleanness Upon 
Removal
400 91.7 ± 10.2 399 88 ± 13.3
Overall Comfort 402 90.8 ± 10.0 400 86 ± 14.2
Comfort at End of Day 402 87.9 ± 12.4 400 83 ± 16.3
Lens Handling 400 95.7 ± 7.4 399 94.5 ± 8.4
Dryness 402 85.4 ± 13.9 400 80.1 ± 16.9
Itchiness 402 92.7 ± 9.5 400 91.3 ± 11.9
Redness 402 92.9 ± 10.3 400 93.5 ± 9.8
Vision 402 95.2 ± 7.2 400 92.4 ± 10.0
Vision in Low Light 402 94.6 ± 7.6 400 92.5 ± 10.3
Vision at End of Day 402 92.7 ± 9.8 400 90.2 ± 11.9
Overall Impression 402 91.3 ± 9.9 400 86.6 ± 14.0
Notes: For each symptom, the score for each subject was obtained as follows: (1) 
the average score across OD and OS was calculated for each visit; (2) the mean of 
these per-visit averages was then calculated across all follow-up visits at which the 
subject presented data on the symptom.
Table 6 Subject-Wise Symptom/Complaint Unfavorable Findings 
Over All Follow-Up Visits
Symptom/Complaint Number/Total (Percent) of 
Subjects Reporting an 
Unfavorable Finding on 




Samfilcon A Balafilcon A
Burning/Stinging Upon 
Insertion
17/400 (4.3) 28/398 (7.0) 0.09
Ease of Handling/Insertion 15/400 (3.8) 12/398 (3.0) 0.70
Vision Upon Insertion 9/400 (2.3) 12/398 (3.0) 0.52
Comfort Upon Insertion 17/400 (4.3) 27/398 (6.8) 0.13
Ease of Handling/Removal 11/400 (2.8) 16/399 (4.0) 0.34
Lens Cleanness Upon 
Removal
23/400 (5.8) 47/399 (12) 0.003*
Overall Comfort 42/402 (10) 74/400 (19) 0.001*
Comfort at End of Day 48/402 (12) 81/400 (20) 0.002*
Lens Handling 6/400 (1.5) 10/399 (2.5) 0.33
Dryness 55/402 (14) 108/400 (27) <0.0001*
Itchiness 49/402 (12) 53/400 (13) 0.67
Redness 54/402 (13) 41/400 (10) 0.19
Vision 23/402 (5.7) 38/400 (9.5) 0.046*
Vision in Low Light 20/402 (5.0) 36/400 (9.0) 0.03*
Vision at End of Day 25/402 (6.2) 41/400 (10) 0.04*
Overall Impression 27/402 (6.7) 50/400 (12) 0.006*
Notes: Unfavorable findings are defined as those with a reported score < 50. The 
reported tally is based upon subjects that presented data for that symptom on at 
least one follow-up visit. †Between-treatment p-value comparing proportions based 
on Fisher’s exact test. *Difference deemed significant at p < 0.05.
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etafilcon A lenses worn in the contralateral eye.26 Further, 
epithelial microcysts were observed in eyes that wore the 
etafilcon A lens, while no hypoxia-related events were 
observed in eyes that wore the balafilcon A lens.
In one study comparing traditional hydrogel to silicone 
hydrogel, the balafilcon A lens worn on a 30-day continuous 
wear basis in one eye performed better than did the etafilcon 
A lens worn on a 7-day extended wear schedule in the other eye 
based upon physiological parameters (epithelial microcysts, 
striae, corneal staining, limbal injection, and bulbar 
injection).27 Further, the study population rated the silicone- 
hydrogel material superior to that of the traditional hydrogel in 
terms of dryness, comfort, lens handling, and overall subjective 
performance. In another study, complication rates in 504 
patients randomized to 30-day continuous wear (353 patients) 
or to 7-day extended wear (151 patients) of balafilcon A lenses 
followed for 12 months were low, with no sight-threatening 
events or difference between 30-day and 7-day wear groups.28
Samfilcon A lenses were initially approved for daily 
wear in 2013,3 and recently for 7-day/6-night extended 
wear;23 to our knowledge, this is the first study to report 
on the performance of the lens worn on an extended wear 
basis. However, forty samfilcon A wearers that wore the 
lens over a three month period and replaced the lens on 
a monthly basis rated the lens highly at all follow-up visits 
(2 weeks, 1 month, 2 months, and 3 months) in terms of 
overall comfort (range 89.1±11.7 at 3 months to 91.1±13.0 
at 2 weeks on a 0–100 point scale), vision (92.0±12.6 to 
93.9±10.5), low-light vision (90.4±12.9 to 93.9±9.6), and 
cleanliness (87.8±12.5 to 91.0±9.8).22 Ratings were not 
different between two-week and one-month visits, nor 
between monthly visits. In contrast, a Johnson & 
Johnson Vision Care-sponsored clinical study comparing 
samfilcon A, senofilcon C, comfilcon A, and lotrafilcon 
B lenses worn on a daily wear basis found that participants 
rated subjective overall comfort of samfilcon A (as well as 
comfilcon A and lotrafilcon B) lenses lower as wear time 
across the monthly replacement interval increased,29 con-
trary to our finding that samfilcon A lenses worn in 7-day 
extended wear mode maintain comfort over each weekly 
wear period, each monthly replacement period, and the 
full year duration of the study. As the former study is not 
published in a peer-reviewed journal, we have no explana-
tion as to the discrepancy.
While samfilcon A lenses are approved for 7-day 
extended wear, balafilcon A and lotrafilcon B (Alcon, Ft. 
Worth, TX) are both approved for 30-day continuous wear. 
The latter two are reported to perform comparably within 
this mode with respect to lens fit, deposition and post-lens 
debris, burning/stinging, dryness, variation in vision, red-
ness, and lens handling.30 However, the authors also 
reported that high contrast visual acuity and subject- 
reported quality of vision were statistically better with 
balafilcon A but not clinically significant. Further, for 
both lenses, limbal and conjunctival redness reduced 
throughout the duration of the study, whereas there was 
a slight increase in the overall amount of corneal staining.
Study Limitations
This study was designed to compare the performance of one 
silicone hydrogel lens recently cleared for EW in the US with one 
cleared decades ago over a 12-month period but not designed to 
determine the change in lens performance over the time course of 
the study. Thus, no inference can be drawn with respect to the 
stability of lens performance over time. The study also did not 
include other silicone hydrogel lenses cleared for either daily 
wear or EW. It would be interesting to compare such lenses from 
different manufacturers to determine which, if any particular lens 
characteristics (eg, material, design, packaging solution) contri-
bute most to lens wear satisfaction.
Conclusion
Samfilcon A silicone hydrogel contact lenses perform com-
parable to or better than do balafilcon A lenses when worn on 
a 7-day extended wear basis, based upon the proportion of 
subjects with slit lamp findings Grade 2 or greater and 
ungraded slit lamp findings on either eye at any follow-up 
visit. In light of this finding, current wearers of samfilcon 
A lenses on a daily wear basis should expect a positive experi-
ence while wearing the lens on a 7-day extended wear basis.
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